London, May 28 (IANS) UK-based AI drug discovery company BenevolentAI has announced to lay off about 180 employees as part of a restructuring plan that resulted from a strategic review, while CFO (Chief Financial Officer) Nicholas Keher has resigned.
According to BusinessCloud, the company will streamline and reorganise operations across two business units -- the Tech Business Unit and the Bio Business Unit, as part of a strategic reorganisation.
The reorganisation is projected to generate net cost savings of 45 million pounds, which includes 13 million pounds from facilities and other operating expenses, as well as 32 million pounds in savings from reduced drug programme and staff costs.
These savings are expected to extend the company's cash runway until at least July 2025, without accounting for any new revenues.
"Embarking on this process requires difficult decisions, particularly concerning our valued colleagues," CEO Joanna Shields was quoted as saying.
"Our new strategic direction ensures we maximise our portfolio and leverage the knowledge and expertise we have built up in recent years to meet this moment of opportunity for AI in biopharma," she added.
As part of its strategic plan, the company may develop a new suite of revenue-generating products to capitalise on the vast potential of AI-driven technologies in the biopharma domain, the report said.
Meanwhile, leading biotechnology company Twist Bioscience Corporation has announced to lay off 270 people, or about 25 per cent of its workforce, as it aims to accelerate its path to profitability.
The company enables customers to succeed through its offering of high-quality synthetic DNA using its silicon platform.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.